The University of Dundee offers a funded 4-year PhD studentship focusing on the investigation of efflux transporter liabilities in bifunctional degraders, with a specific emphasis on their potential in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. This exciting project will explore how targeted protein degraders can cross the blood-brain barrier and develop strategies to optimize their clinical impact. The project, in collaboration with Promega Corporation, provides an annual stipend of £19,236, with funding for tuition fees and research costs. The successful candidate will gain experience in drug design, molecular and cellular biology, and in vitro drug profiling assays, and work closely with industry experts. Applicants should have a degree in a relevant field and be eligible for home fee status. The studentship begins in September 2025.
